Editas Medicine, Inc. (EDIT) has a negative trailing P/E of -1.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -63.84%.
Criteria proven by this page:
Overall SharesGrow Score: 47/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -5.4 | -0.11 | 3.88 | 86.39 | - |
| 2017 | -10.3 | 7.78 | 5.96 | 90.26 | - |
| 2018 | -9.7 | 0.45 | 4.54 | 33.55 | - |
| 2019 | -11.1 | -1.84 | 5.64 | 72.09 | - |
| 2020 | -35.4 | 1.79 | 10.44 | 45.29 | - |
| 2021 | -9.3 | -0.21 | 3.24 | 70.28 | - |
| 2022 | -2.8 | -0.22 | 1.69 | 30.90 | - |
| 2023 | -5.0 | 0.14 | 2.20 | 9.85 | - |
| 2024 | -0.4 | -0.01 | 0.78 | 3.24 | - |
| 2025 | -1.1 | 0.03 | 6.67 | 4.49 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-3.02 | $6.05M | $-97.18M | -1605.5% |
| 2017 | $-2.98 | $13.73M | $-120.32M | -876.5% |
| 2018 | $-2.33 | $31.94M | $-109.95M | -344.3% |
| 2019 | $-2.47 | $20.53M | $-123.47M | -601.4% |
| 2020 | $-1.87 | $90.73M | $-109.41M | -120.6% |
| 2021 | $-2.74 | $25.54M | $-185.11M | -724.7% |
| 2022 | $-2.98 | $19.71M | $-204.35M | -1036.7% |
| 2023 | $-2.02 | $78.12M | $-153.22M | -196.1% |
| 2024 | $-2.88 | $32.31M | $-237.09M | -733.7% |
| 2025 | $-1.80 | $40.52M | $-160.06M | -395% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.06 | $-1.34 – $-0.38 | $27.85M | $6.72M – $76.4M | 8 |
| 2027 | $-0.96 | $-1.37 – $-0.29 | $27.27M | $8.55M – $64.19M | 7 |
| 2028 | $-1.08 | $-1.27 – $-0.95 | $12.2M | $11.81M – $12.59M | 4 |
| 2029 | $-1.06 | $-3.97 – $0.02 | $11.25M | $2.46M – $35.08M | 2 |
| 2030 | $-1.04 | $-3.88 – $0.02 | $21.75M | $4.76M – $67.82M | 2 |
